Figure 2.

Hazard ratios (HRs) for clinical end points associated with baseline levels of biomarkers. Model 1: unadjusted associations, stratified by study. Model 2: adjusted for demographic characteristics (age, sex, race, and body mass index [calculated as the weight in kilograms divided by the height in meters squared]), antiretroviral therapy use, nadir and baseline CD4⁺ T-cell counts, baseline human immunodeficiency virus RNA level, prior AIDS and cardiovascular disease, diabetes mellitus, and hepatitis B virus and hepatitis C virus coinfection, stratified by study. Model 3: HRs for interleukin 6 (IL-6) and D-dimer levels, using model 2 and including both biomarkers simultaneously, and HRs for high-sensitivity C-reactive protein (hsCRP) level, using model 2 and also adjusted for D-dimer level, stratified by study. Abbreviation: CI, confidence interval.